105:
Initially, there is a progressive loss of visual acuity, mostly in one eye. Infected areas experience pigmentation loss in the skin and hair. Unilateral tapetoretinal degeneration accompanied by the ipsilateral appearance of facial
367:
352:
464:
474:
484:
277:
479:
203:
166:
433:
138:
361:
469:
422:
301:
8:
245:
220:
39:
382:
329:
273:
250:
199:
27:
240:
232:
142:
387:
376:
458:
236:
302:"Alezzandrini Syndrome: Practice Essentials, Pathophysiology, Epidemiology"
254:
171:
154:
32:
344:
141:(PUVA) treatment is an option for cases with extensive depigmentation.
417:
393:
82:
442:
150:
146:
111:
107:
94:
90:
86:
81:
is a very rare syndrome characterized by a unilateral degenerative
45:
398:
153:
should wear sunscreen to avoid getting sunburned and developing
371:
356:
428:
130:
The clinical presentation is the basis for the diagnosis.
267:
218:
334:
219:
Gupta M, Pande D, Lehl SS, Sachdev A (August 2011).
196:
193:
122:It is unknown what causes Alezzandrini syndrome.
456:
85:, followed after several months by ipsilateral
268:Rapini RP, Bolognia JL, Jorizzo JL (2007).
295:
293:
291:
289:
114:is the hallmark of Alezzandrini syndrome.
244:
189:
187:
299:
286:
261:
457:
184:
100:
194:James W, Berger T, Elston D (2005).
300:Janniger, Camila K (June 8, 2022).
149:in specific areas. People who have
13:
465:Disturbances of human pigmentation
14:
496:
323:
272:. St. Louis: Mosby. p. 918.
475:Syndromes affecting the retina
212:
1:
177:
485:Syndromes affecting the skin
167:List of cutaneous conditions
133:
125:
89:on the face and ipsilateral
7:
480:Syndromes affecting hearing
198:(10th ed.). Saunders.
160:
139:Psoralen plus ultraviolet A
10:
501:
231:(aug17 1): bcr0420114052.
408:
338:
270:Dermatology: 2-Volume Set
117:
68:
60:
52:
38:
26:
21:
237:10.1136/bcr.04.2011.4052
221:"Alezzandrini syndrome"
44:Loss of vision, facial
434:Alezzandrini syndrome
145:may be used to treat
97:may also be present.
79:Alezzandrini syndrome
22:Alezzandrini syndrome
48:, sound sensitivity
409:External resources
306:Medscape Reference
101:Signs and symptoms
452:
451:
279:978-1-4160-2999-1
76:
75:
16:Medical condition
492:
336:
335:
317:
316:
314:
312:
297:
284:
283:
265:
259:
258:
248:
225:BMJ Case Reports
216:
210:
209:
191:
143:Topical steroids
19:
18:
500:
499:
495:
494:
493:
491:
490:
489:
455:
454:
453:
448:
447:
423:article/1117255
404:
403:
347:
326:
321:
320:
310:
308:
298:
287:
280:
266:
262:
217:
213:
206:
192:
185:
180:
163:
136:
128:
120:
103:
17:
12:
11:
5:
498:
488:
487:
482:
477:
472:
470:Rare syndromes
467:
450:
449:
446:
445:
436:
425:
413:
412:
410:
406:
405:
402:
401:
390:
379:
364:
348:
343:
342:
340:
339:Classification
333:
332:
325:
324:External links
322:
319:
318:
285:
278:
260:
211:
204:
182:
181:
179:
176:
175:
174:
169:
162:
159:
135:
132:
127:
124:
119:
116:
102:
99:
74:
73:
70:
66:
65:
62:
58:
57:
54:
50:
49:
42:
36:
35:
30:
24:
23:
15:
9:
6:
4:
3:
2:
497:
486:
483:
481:
478:
476:
473:
471:
468:
466:
463:
462:
460:
444:
440:
437:
435:
431:
430:
426:
424:
420:
419:
415:
414:
411:
407:
400:
396:
395:
391:
389:
385:
384:
380:
378:
374:
373:
369:
365:
363:
359:
358:
354:
350:
349:
346:
341:
337:
331:
328:
327:
307:
303:
296:
294:
292:
290:
281:
275:
271:
264:
256:
252:
247:
242:
238:
234:
230:
226:
222:
215:
207:
205:0-7216-2921-0
201:
197:
190:
188:
183:
173:
170:
168:
165:
164:
158:
156:
152:
148:
144:
140:
131:
123:
115:
113:
109:
98:
96:
92:
88:
84:
80:
71:
67:
63:
59:
55:
51:
47:
43:
41:
37:
34:
31:
29:
25:
20:
438:
427:
416:
392:
381:
366:
351:
309:. Retrieved
305:
269:
263:
228:
224:
214:
195:
137:
129:
121:
104:
78:
77:
311:January 24,
172:Skin lesion
155:skin cancer
33:Dermatology
459:Categories
383:DiseasesDB
178:References
157:later on.
418:eMedicine
399:403275004
394:SNOMED CT
134:Treatment
126:Diagnosis
83:retinitis
61:Treatment
28:Specialty
443:Q4721578
255:22688932
161:See also
151:vitiligo
147:vitiligo
112:poliosis
108:vitiligo
95:Deafness
91:poliosis
87:vitiligo
46:vitiligo
40:Symptoms
439:Scholia
330:DermNet
246:3171053
72:Unknown
56:Unknown
362:ED63.Y
276:
253:
243:
202:
118:Causes
69:Deaths
53:Causes
388:34138
377:L81.8
429:GARD
313:2024
274:ISBN
251:PMID
229:2011
200:ISBN
110:and
64:None
368:ICD
353:ICD
241:PMC
233:doi
93:.
461::
441::
432::
421::
397::
386::
375::
372:10
360::
357:11
304:.
288:^
249:.
239:.
227:.
223:.
186:^
370:-
355:-
345:D
315:.
282:.
257:.
235::
208:.
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.